SyntekaBio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
SyntekaBio uses artificial intelligence to help drug researchers find and refine promising drug candidates faster, its platforms analyse three-dimensional protein structures and large-scale genomic data to screen compounds and identify targets.
Listed on KOSDAQ, Korea's tech-focused stock exchange, it supplies these AI-driven drug-discovery services to pharmaceutical and biotech clients, and its genomic precision-medicine platform is already generating revenue through domestic university hospitals. Its own internal drug pipeline, covering synthetic drugs, drug repurposing, and antibody therapies, runs alongside the platform services business.
Summary is AI-generated and may contain errors · figures from DART filings
SyntekaBio's supercomputing and big-data infrastructure originated partly through a technology contribution from ETRI, Korea's state-run electronics and telecommunications research institute.
SyntekaBio in five facts
What does SyntekaBio do?
SyntekaBio uses artificial intelligence to help drug researchers find and refine promising drug candidates faster, its platforms analyse three-dimensional protein structures and large-scale genomic data to screen compounds and identify targets.
Where is SyntekaBio listed and in which sector?
SyntekaBio (Korean name: 신테카바이오) trades under KRX code 226330 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Information Technology sector, Software.
How large is SyntekaBio?
Its market capitalisation was US$18.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were SyntekaBio's latest annual revenue and operating profit?
For fiscal year 2025, SyntekaBio reported revenue of US$2.6M, an operating loss of US$8.1M and a net loss of US$13.1M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 2736.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Results of extraordinary shareholders' meetingOct 16
- Grant of stock optionsOct 16
- Shareholder register closure / record date setOct 14
- Resolution to convene a general shareholders' meeting (extraordinary meeting)Oct 14
- Report on large shareholdings (5% rule) (abbreviated)Oct 12
- [Amended] Resolution to convene a general shareholders' meetingSep 30
- [Amended] Share-pledge agreement that may change the largest shareholder
SyntekaBio's largest shareholder (an individual) pledged shares as loan collateral, securing up to US$3.71M.
Ownership change · Sep 30 · 6 versions - [Amended] Proxy solicitation reference documentSep 30
- [Amended] Notice of general shareholders' meetingSep 30
- Material event report (decision to redeem own convertible bonds early)Capital raise · Sep 14
- Material event report (decision to redeem own convertible bonds early)Capital raise · Sep 14
- Supply contract signed
SyntekaBio disclosed a supply contract with Geovista Co., Ltd., worth US$393K, about 15.46% of its recent annual revenue, running through Sep 2026.
Supply contract · Sep 11 - [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Sep 11
- [Amended] Notice of general shareholders' meetingSep 11
- [Amended] Proxy solicitation reference documentSep 11
- [Amended] Small public offering disclosure (equity)Sep 4
- [Amended] Material event report (rights offering)
SyntekaBio updated the terms of a private placement (third-party allotment) to raise US$1.48M, about 6.4% of its market value.
Capital raise · Sep 4 · 4 versions - Rights offering: final issue price set
SyntekaBio Co., Ltd. finalized the issue price for its third-party-allotted small-scale public offering of 1,616,814 registered common shares (par value US$0.37) at US$0.91 per share, determined on 2026-09-01 by applying a 10% discount to the volume-weighted average share price.
Capital raise · Sep 2 - [Amended] Small public offering disclosure (equity)Sep 2
- Proxy solicitation reference documentSep 2
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Aug 31
- Notice of general shareholders' meetingAug 31
- Material event report (decision to redeem own convertible bonds early)
SyntekaBio Co., Ltd. decided to acquire before maturity US$648K of the face amount of its Series 4 privately placed convertible bond for US$681K by mutual agreement with the bondholder, leaving no remaining face balance.
Capital raise · Aug 19 - Supply contract signed
SyntekaBio disclosed a supply contract with AtoResearch Co., Ltd., worth US$4.3M, about 188.96% of its recent annual revenue, running through Oct 2029.
Supply contract · Jul 9 - [Amended] Supply contract signed
SyntekaBio updated a previously disclosed supply contract with Rudacure Co., Ltd., now worth US$268K, about 324.13% of its recent annual revenue, running through Jun 2026.
Supply contract · May 28 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · May 8
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SyntekaBio reported consolidated results for FY2025: revenue of US$2.37M (+2736.7% year on year), an operating loss of US$7.36M and a net loss of US$12.1M.
Earnings · Feb 12